search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
CLINICAL ISSUES :: LIQUID BIOPSIES


limitations of liquid biopsy in oncology care. Investiga- tions and clinical trials are ongoing into the utilization of this technology for early diagnosis, treatment response and recurrence monitoring, evaluation of clonal evolu- tion and resistance, and even as a screening tool to help detect cancers early. For now, liquid biopsy applications need to stay within the intended use population of advanced cancers when tissue is not available, and the results need to be used in conjunction with other clinical data from imaging and tissue biopsies. For all the potential in liquid biopsy diagnostics, tissue will remain at the core of cancer diag- nosis, prognostication, and therapy selection for now.


REFERENCES


1. Wan JCM, et al. Liquid biopsies come of age: towards implementation of circulating tumor DNA. Nat Rev Cancer. 2017 Apr; 17(4):223-232.


2. Dominguez-Vigil IG,. et al. The dawn of the liquid biopsy in the fight against cancer. Oncotarget. 2017 Dec 8;9(2):2912-2922.


3. NCI Dictionary of Cancer Terms. National Cancer Institute. https://www. cancer.gov/publications/dictionaries/cancer-terms/def/liquid-biopsy. Published 2019. Accessed April 15, 2019.


4. Statistics Market Research Consulting, “Liquid biopsy – global market outlook (2017-2023)” 2017. Available at: https://bit.ly/2SmkGW2. Accessed April 15, 2019.


5. Lynette M. Sholl. October 9, 2018. Liquid Biopsies – Promises and Pitfalls. [Webinar]. In Advancing Patient Care in NSCLC: Breaking Down Barriers. Retrieved from http://educate.amp.org/store/seminar/seminar. php?seminar=135840


6. Muller JN, et al. Concordance between comprehensive cancer genome profiling in plasma and tumor specimens. J Thorac Oncol. 2017 Oct;12(10):1503-1511.


Nathan McNeill, PhD, serves as Director of Molecular Assay Development and a Medical Science Liaison at MedFusion, a Quest Diagnostics company. He has extensive experience in human genetics and molecular diagnostics with over 10 years of research experience.


Greg Baschkopf serves as Product Director for Solid Tumor Profiling at Quest Diagnostics. He has more than 10 years of experience in the molecular diagnostic lab industry. His career began in the lab and he has held positions in sales, training and product management.


7. National Comprehensive Cancer Network. (2019). Non-Small Cell Lung Cancer (Version 3.2019 – January 18, 2019). Retrieved from https://www. nccn.org/professionals/physician_gls/pdf/nscl.pdf


8. Lindeman NI, et al. 2018. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors. J Thorac Oncol. 2018 Mar;13(3):323-358.


9. Stetson D, et al. Orthogonal comparison of four plasma NGS tests with tumor suggests technical factors are a major source of assay discordance. JCO Precison Oncology 2019 3:1-9.


10. CMS.gov. MolDX: Guardant360 Plasma-Based Comprehensive Genomic Profiling in Non-Small Cell Lung Cancer (NSCLC). 8/27/18. 3/29/19.


11. CMS.gov. MolDX: Guardant360 Plasma-Based Comprehensive Genomic Profiling in Solid Tumors. 3/28/19. 3/29/19.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72